As DNA-PK is a core component of the classical non-homologous end-joining (c-NHEJ) pathway (Fig. 2G) and radiosensitivity of c-NHEJ deficient tumour cells has been observed [57, 58], the patient completed a course of stereotactic ablative radiotherapy to one additional chest wall nodule and concurrent radiation to a pelvic nodule, then continued with olaparib as maintenance therapy. This evidence concerns the gene PRKDC and neoplasm.